Friedreich Ataxia News: Latest Research and Treatment Developments

Friedreich ataxia, also called FA or FRDA, is a rare disease that affects about 1 in every 50,000 people in the United States. Research on Friedreich ataxia may not make major headlines, but if you or your child is living with the condition, any news or updates can feel important.

Friedreich ataxia gets worse over time and can damage the brain and spinal cord, often starting at a young age. It can also cause serious heart problems and may shorten a person’s life. There’s no cure yet, but researchers are working to improve how the condition is diagnosed and treated.

FDA Approved the First Treatment for Friedreich Ataxia

The biggest Friedreich ataxia news in the past decade was the 2023 approval of omaveloxolone (Skyclarys) by the U.S. Food and Drug Administration (FDA). It is a capsule taken by mouth once a day on an empty stomach.

Researchers studied whether the drug could help slow the progression of Friedreich ataxia. They based their assessment on the modified Friedreich Ataxia Rating Scale (mFARS) score. This test checks common signs that Friedreich ataxia is getting worse, including:

• How well the arms and legs move
• Changes in speech
• Trouble swallowing
• Balance while standing

After 48 weeks, people taking omaveloxolone had better mFARS scores than those taking a placebo (inactive treatment). When researchers followed up three years later, they found that people taking omaveloxolone were doing better than those who were not taking it.

Orphan Drug Designation Given for SGT-212 Gene Therapy

In January 2026, the FDA gave orphan drug designation to SGT-212, a gene therapy being developed to treat Friedreich ataxia. Orphan drug designation is a special status for treatments for rare diseases. It gives drug companies support, such as tax credits and lower fees, to help them develop these treatments.

SGT-212 is a gene replacement therapy. Healthcare providers deliver it into the body through an infusion. This therapy increases levels of frataxin (FXN), a protein that people with Friedreich ataxia can’t make enough of. The goal of treatment is to help prevent Friedreich ataxia from damaging the heart, brain, and other body systems.

People with Friedreich ataxia ages 18 to 40 may be able to get SGT-212 through a clinical trial in the United States. The first study is planned to last five years. The results of this research will help guide future studies.

Nomlabofusp Received Breakthrough Therapy Designation

In February 2026, another potential treatment received breakthrough therapy designation from the FDA. Nomlabofusp is a frataxin protein replacement therapy that has shown promise for adults and children with Friedreich ataxia.

Early research suggests that after one year of treatment, people with Friedreich ataxia were more likely to see improvements in several tests that monitor Friedreich ataxia progression, including:

• mFARS score
• FARS-Activities of Daily Living
• Nine-Hole Peg Test
• Modified Fatigue Impact Scale

Breakthrough therapy designation is different from orphan drug designation. Instead of giving companies financial incentives, it helps speed up the review process and makes it easier to move the treatment through testing.

Grant Funded for Understanding of Friedreich Ataxia Genetics

The U.S. Department of Defense awarded Sanjay Bidichandani, a professor of pediatrics at the University of Oklahoma College of Medicine, $2.8 million to expand his research on the genetic traits of Friedreich ataxia.

In 1996, researchers (including Bidichandani) found differences in the FXN gene responsible for Friedreich ataxia. People with Friedreich ataxia have a longer sequence of the code “GAA” in this gene. Those without the condition have fewer than 30 consecutive “GAA” codes. People with Friedreich ataxia have 100 to 1,500 consecutive GAA codes.

New research suggests the genetics of Friedreich ataxia aren’t as straightforward as previously thought. Newer technology has uncovered “spelling errors” in the expanded GAA sequences associated with Friedreich ataxia. Sometimes, the Gs and As are scrambled up. As a result, Friedreich ataxia isn’t found during routine testing, and the correct diagnosis may be missed.

Bidichandani’s team used long-read sequencing to spot these differences. Their ongoing research aims to make the process of diagnosing Friedreich ataxia more accurate. They also hope to offer families better screening to assess their risk of passing Friedreich ataxia to their children.

Millions Awarded for Gene-Editing Research

In January 2026, the California Institute for Regenerative Medicine (CIRM) gave the University of California $7.4 million to work on a new type of gene therapy for Friedreich ataxia.

For this treatment, immature blood-forming cells are removed from the body. Then, gene-editing technology (CRISPR/Cas9) is used to fix the genetic mutation (gene change) that causes Friedreich ataxia. These modified cells are put back in the body, where they develop into different tissues.

The hope is that this procedure can provide long-term benefits, restoring normal levels of frataxin and preventing Friedreich ataxia complications. This phase of the project is the last step before researchers can apply to test it in humans. It’ll help confirm the safety of this ataxia treatment and plan for clinical trials that could lead to new treatments for people with Friedreich ataxia.

Study Provided New Insight To Predict Heart Problems

Some people with Friedreich ataxia develop severe heart problems that can be life-threatening. But not all heart problems are this serious. Unfortunately, doctors aren’t sure how to predict this risk. However, a recent study provided some potential clues.

The heart can use fat or sugar for fuel. Being able to switch between energy sources helps the heart stay healthy. Fat is the heart’s preferred fuel. But when there’s a problem, it can use glucose (sugar) instead because the process of turning glucose into energy doesn’t require as much oxygen. Although glucose can be used efficiently, it does not provide as much energy as fat.

Researchers looked at how the hearts of a small group of people with Friedreich ataxia used fuel. They found that people with Friedreich ataxia whose hearts relied more heavily on glucose were also more likely to have ongoing heart damage and a risk of heart problems such as cardiomyopathy.

Learning more about the subtle signs of trouble may help people with Friedreich ataxia get an earlier start in protecting their hearts.

Join the Conversation

On MyAtaxiaTeam, people share their experiences with Friedreich ataxia, get advice, and find support from others who understand.

What are your thoughts on the latest medical research initiatives and therapeutic approaches for Friedreich ataxia? Let others know in the comments below.